Randomized Trialhigh evidence
Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial.
Nature medicine·November 9, 2026·PMID 43003902
Why it mattersGLP-1 receptor agonist therapy often reduces lean mass alongside fat, raising concerns about muscle function and long-term metabolic health. This trial provides direct evidence that structured resistance training can preserve muscle and strength during tirzepatide treatment without compromising weight loss.

The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled